CR20170590A - Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen - Google Patents

Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen

Info

Publication number
CR20170590A
CR20170590A CR20170590A CR20170590A CR20170590A CR 20170590 A CR20170590 A CR 20170590A CR 20170590 A CR20170590 A CR 20170590A CR 20170590 A CR20170590 A CR 20170590A CR 20170590 A CR20170590 A CR 20170590A
Authority
CR
Costa Rica
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
acid derivatives
hydroxy acid
Prior art date
Application number
CR20170590A
Other languages
English (en)
Spanish (es)
Inventor
James Edward Paul Davidson
Attila Paczal
James Brooke Murray
András Kotschy
Olivier Geneste
Szabolcs Sipos
Maïa Chanrion
Balázs Bálint
Zoltán Szlávik
Ágnes Proszenyák
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Priority claimed from PCT/EP2016/064417 external-priority patent/WO2016207216A1/en
Publication of CR20170590A publication Critical patent/CR20170590A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR20170590A 2015-06-23 2016-06-22 Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen CR20170590A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1555747A FR3037956B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2016/064417 WO2016207216A1 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
CR20170590A true CR20170590A (es) 2018-02-26

Family

ID=54260901

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20170590A CR20170590A (es) 2015-06-23 2016-06-22 Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20170571A CR20170571A (es) 2015-06-23 2016-06-22 Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmaceúticas que los contienen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20170571A CR20170571A (es) 2015-06-23 2016-06-22 Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmaceúticas que los contienen.

Country Status (42)

Country Link
US (1) US10457687B2 (enExample)
EP (1) EP3313850B1 (enExample)
JP (1) JP6741698B2 (enExample)
KR (1) KR102620905B1 (enExample)
CN (1) CN107709334B (enExample)
AR (1) AR105101A1 (enExample)
AU (1) AU2016282837B2 (enExample)
CA (1) CA2990089C (enExample)
CL (1) CL2017003163A1 (enExample)
CO (1) CO2017012830A2 (enExample)
CR (2) CR20170590A (enExample)
CU (1) CU20170164A7 (enExample)
CY (1) CY1120991T1 (enExample)
DK (1) DK3313850T3 (enExample)
EA (1) EA034587B1 (enExample)
EC (1) ECSP17082546A (enExample)
ES (1) ES2703997T3 (enExample)
FR (1) FR3037956B1 (enExample)
GE (1) GEP20207075B (enExample)
HK (2) HK1250234A1 (enExample)
HR (1) HRP20181806T1 (enExample)
IL (1) IL256191B (enExample)
JO (1) JO3430B1 (enExample)
LT (1) LT3313850T (enExample)
MA (1) MA42232B1 (enExample)
MD (1) MD3313850T2 (enExample)
MX (1) MX368845B (enExample)
MY (1) MY189472A (enExample)
PE (1) PE20190111A1 (enExample)
PH (1) PH12017502266B1 (enExample)
PL (1) PL3313850T3 (enExample)
PT (1) PT3313850T (enExample)
RS (1) RS57961B1 (enExample)
RU (1) RU2747673C2 (enExample)
SA (1) SA517390583B1 (enExample)
SI (1) SI3313850T1 (enExample)
SV (1) SV2017005588A (enExample)
TN (1) TN2017000521A1 (enExample)
TW (1) TWI631124B (enExample)
UA (1) UA123267C2 (enExample)
UY (1) UY36733A (enExample)
WO (1) WO2016207226A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CN110381937A (zh) 2017-01-06 2019-10-25 法国施维雅药厂 Mcl-1抑制剂和紫杉烷化合物的组合及其用途和药物组合物
WO2018234433A1 (en) 2017-06-22 2018-12-27 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
EP3652184A1 (en) 2017-08-15 2020-05-20 AbbVie Inc. Macrocyclic mcl-1 inhibitors and methods of use
WO2019035899A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
TW202100184A (zh) 2019-05-20 2021-01-01 瑞士商諾華公司 Mcl-1抑制劑抗體-藥物結合物及使用方法
TW202114682A (zh) 2019-06-17 2021-04-16 法商施維雅藥廠 Mcl-1抑制劑與乳癌標準療法之組合,其用途及醫藥組合物
CN112457308B (zh) 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP4351564A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
EP4525927A1 (en) 2022-05-20 2025-03-26 Novartis AG Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96531A (en) * 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
JP5502072B2 (ja) * 2008-04-30 2014-05-28 ナショナル ヘルス リサーチ インスティテューツ オーロラキナーゼ阻害剤としての縮合二環式ピリミジン化合物
WO2012044993A1 (en) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
MX336549B (es) * 2010-12-20 2016-01-22 Glenmark Pharmaceuticals Sa Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1.
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2014078957A1 (en) 2012-11-20 2014-05-30 The Royal Institution For The Advancement Of Learning/Mcgill University Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
US20190031675A1 (en) 2019-01-31
SA517390583B1 (ar) 2022-02-20
MY189472A (en) 2022-02-16
RU2018102372A3 (enExample) 2019-11-06
RU2747673C2 (ru) 2021-05-12
UA123267C2 (uk) 2021-03-10
SI3313850T1 (sl) 2019-01-31
MX368845B (es) 2019-10-18
RU2018102372A (ru) 2019-07-23
CO2017012830A2 (es) 2018-03-28
IL256191B (en) 2020-03-31
KR102620905B1 (ko) 2024-01-04
CN107709334A (zh) 2018-02-16
CR20170571A (es) 2018-02-20
FR3037956A1 (enExample) 2016-12-30
ECSP17082546A (es) 2018-02-28
IL256191A (en) 2018-02-28
UY36733A (es) 2016-12-30
PL3313850T3 (pl) 2019-04-30
NZ738459A (en) 2024-05-31
EA034587B1 (ru) 2020-02-25
TW201712018A (zh) 2017-04-01
BR112017027645A2 (pt) 2018-08-28
HK1252113A1 (en) 2019-05-17
PT3313850T (pt) 2018-11-29
CL2017003163A1 (es) 2018-06-15
HK1250234A1 (zh) 2018-12-07
JO3430B1 (ar) 2019-10-20
LT3313850T (lt) 2018-11-26
EA201890123A1 (ru) 2018-05-31
CA2990089C (en) 2020-11-03
AU2016282837A1 (en) 2018-01-18
KR20180015261A (ko) 2018-02-12
HK1252113B (en) 2020-01-10
EP3313850B1 (en) 2018-10-03
MA42232A (fr) 2016-12-29
DK3313850T3 (en) 2019-01-28
SV2017005588A (es) 2018-06-01
PH12017502266B1 (en) 2021-01-13
CA2990089A1 (en) 2016-12-29
FR3037956B1 (fr) 2017-08-04
US10457687B2 (en) 2019-10-29
MX2017016996A (es) 2018-08-23
TWI631124B (zh) 2018-08-01
JP6741698B2 (ja) 2020-08-19
PE20190111A1 (es) 2019-01-15
TN2017000521A1 (en) 2019-04-12
GEP20207075B (en) 2020-03-10
AR105101A1 (es) 2017-09-06
HRP20181806T1 (hr) 2018-12-28
PH12017502266A1 (en) 2018-06-11
MD3313850T2 (ro) 2019-02-28
EP3313850A1 (en) 2018-05-02
ES2703997T3 (es) 2019-03-13
CY1120991T1 (el) 2019-12-11
CN107709334B (zh) 2021-04-13
MA42232B1 (fr) 2018-11-30
JP2018522856A (ja) 2018-08-16
CU20170164A7 (es) 2018-05-08
AU2016282837B2 (en) 2020-05-28
RS57961B1 (sr) 2019-01-31
WO2016207226A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
DOP2017000304A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17083003A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2018000270A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2017016997A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
NI201800076A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20140143A7 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN